Answers are grounded in this paper and cite their sources.
This study investigated the expression of miR-155 and miR-223 in Iraqi patients with acute and chronic hepatitis C virus (HCV) infection to explore their potential roles in immune modulation and as biomarkers. A total of 242 individuals suspected of HCV infection were screened, of whom 40 were HCV RNA-positive and classified into acute (n=20) and chronic (n=20) infection groups. Twenty healthy controls were also included. Participants were recruited from the Hepatology and Gastroenterology Teaching Hospital in Baghdad, Iraq. Expression levels of miR-155 and miR-223 were measured using quantitative polymerase chain reaction (qPCR), normalized to GAPDH, and calculated using the 2^−ΔΔCt method. MiR-155 expression was significantly higher in acute (3.05 ± 0.35) and chronic (3.82 ± 0.34) HCV groups than in healthy controls (1.34 ± 0.19). MiR-223 expression was significantly higher in chronic HCV infection (2.35 ± 0.37) than in acute infection (1.55 ± 0.22) and healthy controls (1.10 ± 0.11). These findings indicate that miR-155 is upregulated in both acute and chronic HCV infection, whereas miR-223 shows greater expression in chronic infection. Both miRNAs may contribute to immune modulation during HCV infection and warrant further investigation as potential biomarkers of disease progression.
No takes yet. Share an insight, caveat, or question.
Alazzawi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: